Figures computed from official regulatory filings — .
Ownershipinsiders 17.46% · institutions 11.46%
In EUR · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for INNATE PHARMA only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Market information source · Oct 19, 2026
Open-market timeline · full history
21 buys37 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Bpifrance Participations SAtrack record | Award | $3.5M | AMF |
| Nicola Beltraminelli | Buy | $94.4K | conv 73ClusterFirst in 12mo | AMF |
| FREDERIC LOMBARD | Buy | $94.4K | conv 82Cluster | AMF |
| Nicola Beltraminelli | Sell | $8.1K | AMF |
| Nicola Beltraminelli | Sell | $5.5K | AMF |
| Nicola Beltraminelli | Sell | $8K | AMF |
| Nicola Beltraminelli | Sell | $5.5K | AMF |
| Nicola Beltraminelli | Sell | $9.4K | AMF |
| YANNIS MORELtrack record | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 73Cluster | AMF |
| ODILE BELZUNCE | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 73Cluster | AMF |
| Claire de Lingua de Saint Blanquat | Buy | $47.2K | conv 73Cluster | AMF |
| YANNIS MORELtrack record | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 73Cluster | AMF |
| ODILE BELZUNCE | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 83ClusterFirst in 12mo | AMF |
| FREDERIC LOMBARD | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 82ClusterFirst in 12mo | AMF |
| Eric Vivier | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 67Cluster | AMF |
| Henry Wheeler | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | AMF |
| Claire de Lingua de Saint Blanquat | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 73ClusterFirst in 12mo | AMF |
| YANNIS MORELtrack record | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 59First in 12mo | AMF |
| Eric Vivier | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 50First in 12mo | AMF |
| ODILE BELZUNCE | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 81ClusterFirst in 12mo | AMF |
| mondher mahjoubi | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | AMF |
| Odile LAURENT | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 75ClusterFirst in 12mo | AMF |
| mondher mahjoubi | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | AMF |
| YANNIS MORELtrack record | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 77Cluster | AMF |
| Eric Vivier | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 71Cluster | AMF |